Gene expression analysis market is forecasted to value over CAGR of over 9.9% by 2028 end.
The increasing prevalence, decreasing cost of sequencing and the rising application areas of genomics are fueling the growth of market. In addition, the increasing focus on advanced healthcare system alongside growing preference towards advanced technology in drug development and modern diagnostics is driving the market. Implementation of an initiative like the Precision Medicine Initiative (PMI) has boosted the market growth.
The gene expression analysis market is bifurcated into by process, by product, by capacity, by technique, by application, and by region. In terms of process, PCR analysis is expected to hold a major share of the market owing to the frequent upgradations deployed in qPCR and high adoption of these systems. Moreover, the integration of these systems with other steps is positively influencing the market. PCR analysis is prominently preferred by biologists to study the expressions of multiple microorganisms.
Based on product, kits
reagents are expected to dominate the market owing to its low price and enhanced efficiency. Due to its low price, there has been a high usage of these products. The introduction of novel kits and reagents has increased sales thus propelling the market. Furthermore, increasing demand for better visualization and data interpretation is resulting in prominent players enhancing bioinformatics tools, thus expanding the gene expression analysis market size.
In terms of capacity, low to mid plex is expected to show notable growth. Advancements in stem cell research and an increase in the number of research projects related to single-cell analysis are the major factors expanding the market. Additionally, the development of multiplexed digital characterization systems is positively influencing the market.
Based on the technique, RNA expression is the front runner of the market. The rising demand for DNA microarrays and PCR analysis has resulted in the inflation of the market. Besides, the integration of immunoprecipitation assay with these techniques has also positively influenced the market. The emergence of upcoming next-generation sequencing is expected to propagate the market growth further.
In terms of application, drug development is expected to control the growth of the market. Factors such as high cost and time have gathered the interest of prominent pharmaceutical players to invest in it. The commercial launch aspect has played a catalyst role in the growth of the market.
North America is forecasted dictate market growth. Development of gene therapy, availability of NGS funding and government initiatives are the key factors bolstering the market in the region. Asia-Pacific region represents a lucrative opportunity for manufacturers owing to increasing domestic manufacturing for sequencing systems and increasing bioresearch centres. Furthermore, a rise in the research
development activities and improving healthcare infrastructure is accelerating the growth of the market in the region.
Thermo Fisher Scientific, Illumina, Inc., Agilent Technologies, QIAGEN N.V, PerkinElmer, BGI, GE Healthcare, Hoffman-La Roche Ltd, Bio-Rad Laboratories, Inc. and Pacific Biosciences of California, Inc.